Vabysmo 120 mg/mL solution for injection
Sponsors
Martin-Luther-Universitaet Halle-Wittenberg, Medical University Of Graz, Medical University Of Graz, Medical University Of Graz, Association For Innovation And Biomedical Research On Light And Image, F. Hoffmann-La Roche AG
Conditions
Macular edemaNeovascular Age-Related Macular DegenerationNeovascular age-related macular degenerationpolypoidal choroidal vasculopathy
Phase 3
Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)
CompletedCTIS2024-515377-10-00
Start: 2023-06-12End: 2025-02-26Target: 70Updated: 2024-11-18
A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients with Neovascular Age-Related Macular Degeneration (CONSTANCE)
RecruitingCTIS2024-517545-13-00
Start: 2025-06-04Target: 89Updated: 2026-01-21
Phase 4
Two initial faricimab loading doses in treatment-naive neovascular AMD
RecruitingCTIS2024-514408-15-00
Start: 2024-11-14Target: 50Updated: 2024-10-14
A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasian patients with polypoidal choroidal vasculopathy
RecruitingCTIS2024-515640-22-00
Start: 2025-08-06Target: 90Updated: 2025-08-18
A phase IV study of Faricimab to explore associations of visual acuity benefits and changes in vascular integrity using adaptive optics in patients with diabetic macular edema
RecruitingCTIS2023-509829-52-00
Start: 2025-09-01Target: 170Updated: 2026-01-13